

# Optimizing Patient Outcomes in Castration-Resistant Prostate Cancer: Moving Urologists From Knowledge to Action

## Abbreviations, Acronyms, Initialisms

|                |  |
|----------------|--|
| <b>AA</b>      | abiraterone acetate                                    |
| <b>ADT</b>     | androgen deprivation therapy                           |
| <b>AE</b>      | adverse event  |
| <b>ALP</b>     | alkaline phosphatase                                   |
| <b>ALT</b>     | alanine aminotransferase                               |
| <b>ANC</b>     | absolute neutrophil count                              |
| <b>A/O</b>     | abiraterone acetate or orteronel                       |
| <b>API</b>     | androgen pathway inhibitor                             |
| <b>AR</b>      | androgen receptor                                      |
| <b>ASCO</b>    | American Society of Clinical Oncology                  |
| <b>AST</b>     | aspartate aminotransferase                             |
| <b>ATA</b>     | anti-therapeutic antibody                              |
| <b>AUA</b>     | American Urological Association                        |
| <b>BPI</b>     | Brief Pain Inventory                                   |
| <b>BSC</b>     | best supportive care                                   |
| <b>CAR</b>     | carboplatin  |
| <b>CBZ</b>     | cabazitaxel  |
| <b>CBZP</b>    | cabazitaxel + prednisone                               |
| <b>CEA</b>     | carcinoembryonic antigen                               |
| <b>CI</b>      | confidence interval                                    |
| <b>CIS</b>     | cisplatin  |
| <b>CRPC</b>    | castration-resistant prostate cancer                   |
| <b>DC</b>      | dendritic cell   |
| <b>DOC</b>     | docetaxel  |
| <b>DOX</b>     | doxorubicin  |
| <b>E</b>       | enzalutamide   |
| <b>EBRT</b>    | external beam radiation therapy                        |
| <b>ECOG-PS</b> | Eastern Cooperative Oncology Group- Performance Status |
| <b>ENZ</b>     | enzalutamide   |
| <b>EOD</b>     | extent of disease                                      |
| <b>ETO</b>     | etoposide  |
| <b>FACT-P</b>  | Functional Assessment of Cancer Therapy- Prostate      |
| <b>GS</b>      | Gleason score  |
| <b>Hb</b>      | hemoglobin   |
| <b>HR</b>      | hazard ratio   |

# Optimizing Patient Outcomes in Castration-Resistant Prostate Cancer: Moving Urologists From Knowledge to Action

|                 |  |
|-----------------|--|
| <b>HT</b>       | hormone therapy  |
| <b>IHC</b>      | immunohistochemical  |
| <b>imRECIST</b> | immune-modified Response Evaluation Criteria in Solid Tumors |
| <b>ITT</b>      | intent-to-treat  |
| <b>LFT</b>      | liver function test  |
| <b>mCRPC</b>    | metastatic castration-resistant prostate cancer              |
| <b>met</b>      | metastases   |
| <b>MMR</b>      | mismatch repair  |
| <b>MoCA</b>     | Montreal Cognitive Association                               |
| <b>mos</b>      | months   |
| <b>MP</b>       | mitoxantrone + prednisone                                    |
| <b>MSI</b>      | microsatellite instability                                   |
| <b>NCCN</b>     | National Comprehensive Cancer Network                        |
| <b>NS</b>       | not significant  |
| <b>ORR</b>      | objective response rate                                      |
| <b>OS</b>       | overall survival   |
| <b>P</b>        | prednisone   |
| <b>PARP</b>     | poly ADP ribose polymerase                                   |
| <b>Pbo</b>      | placebo  |
| <b>PCA</b>      | paclitaxel   |
| <b>PCWG</b>     | prostate cancer working group                                |
| <b>PD-L1</b>    | programmed death ligand-1                                    |
| <b>PFS</b>      | progression-free survival                                    |
| <b>PK</b>       | pharmacokinetics   |
| <b>Plt</b>      | platelets  |
| <b>PR</b>       | partial response   |
| <b>PRED</b>     | prednisone   |
| <b>PSA</b>      | prostate specific antigen                                    |
| <b>PSADT</b>    | prostate specific antigen doubling time                      |
| <b>RECIST</b>   | Response Evaluation Criteria in Solid Tumors                 |
| <b>rPFS</b>     | radiographic progression-free survival                       |
| <b>SRE</b>      | skeletal-related event                                       |
| <b>SSE</b>      | symptomatic skeletal event                                   |
| <b>TEAE</b>     | treatment-emergent adverse event                             |
| <b>TTP</b>      | time to prostate specific antigen progression                |
| <b>WNL</b>      | within normal limits   |